Market temperatures are slowly rising with the summer heat. With some stocks posting double-digit gains, overvaluation concerns are becoming rife. Nevertheless, the focus is increasingly on under-the-radar gems, showing the tremendous potential of breaking out backed by game-changing innovations and products. Here are the top four stocks that could outperform in the coming sessions.
Epazz, Inc. (OTC: EPAZ)
Epazz, Inc. (OTC: EPAZ) is one stock displaying promising indicators as it continues to strengthen its edge and prospects as a provider of drone technology, artificial intelligence, and cryptocurrency apps.
The company, which was issued its third patent for its ZenaDrone 1000 artificial intelligence-powered drone on August 1, 2023, affirms it has a promising technology that should be a game changer for many years to come. The patent covers the unique design of the ZenaDrone 1000, which is a multifunctional unmanned aerial vehicle equipped with machine learning systems and AI technology.
The new patent further secures Epazz's technology and strengthens its patent portfolio, from which it is expected to generate significant value. The company has already applied for other patents and plans to apply for more in the future to build a portfolio of drone patents to create added value.
CEO Shaun Passley, Ph.D., said, "We are manufacturing over 30 drones that will be used for our customers in Ireland and the U.S. The new patent further secures our technology."
Through its ZenaDrone subsidiary, Epazz is focused on improving intelligent UAV technology while leveraging the capabilities of machine learning software and AI. The autonomous drone offers full surveillance, inspection, and monitoring solutions thanks to innovative software technology on compact, rugged hardware engineered for various applications.
The multifunctional unmanned aerial vehicle continues to elicit strong interest from various industries, including military construction and agriculture operations. The company is manufacturing over 30 drones, including 20 drones that will be used in Ireland. The company's receipt of a letter of support from the US Air Force underscores ZenaDrone 1000's credibility and edge for military operations. Consequently, the company has set sights on several opportunities in the US military, seen as a key avenue for generating value.
The ZenaDrone 1000 technology has also garnered strong interest from the agriculture, oil and gas, wildfire, and civil engineering industries. The strong interest stems from the fact that the technology is highly suited for autonomous navigation of unmapped terrain and deep learning that enables commercial and military drone utilization.
Epazz has already inked a deal with Night Sun LLC that will result in the manufacture and sale of the ZenaDrone 1000 on Native American tribal lands. The joint venture was confirmed on July 27. 2023 will pave the way for the manufacture of ZenaDrone 1000 for use by the US government military, and State governments.
CEO Shaun Passley, Ph.D., said, "We are excited about forming this joint venture with Night Sun, LLC. Many Native American tribes are ready to use ZenaDrone 1000; we needed to find a way to sell into the market."
The deal comes on the game-changing ZenaDrone 1000, eliciting strong interest from Native American tribes. Consequently, there are plans to set up a drone manufacturing facility on the tribal lands, which should provide the company with tax and contract benefits. The first 10 drones to be produced from the facility are to function as service drones and are expected to generate over $100,000 per drone per year.
Even as Epazz continues to pursue growth opportunities around ZenaDrone 1000, it has also set its sights on the burgeoning blockchain and cryptocurrency sectors. On July 19, 2023, the company unveiled CryObo technologies that will help farmers tokenize their crops by using non-fungible token technology in the race to earn extra revenue. The company is working with CryObo Software to enable the tokenization of farm crops and produce as it seeks to provide farmers with a new way of raising capital.
RespireRx Pharmaceuticals Inc. (OTC:RSPI)
RespireRx Pharmaceuticals Inc. (OTC:RSPI) operates through its subsidiaries and business units, which are collectively called RespireRx Group. The company is involved in the discovery and development of medicines for treating neurological and psychiatric conditions.
On August 9, RespireRx Pharmaceuticals announced that one of its subsidiaries had reached a key agreement with the Australian unlisted public company ResolutionRx Ltd. In a joint announcement, the company announced that, as per the agreement, on August 3, 2023, the two companies entered into a range of bilateral agreements. The aim of the agreements was to move the pharmaceutical CBD program at RespireRx to ResolutionRx.
"Since the incorporation of ResolutionRx at the beginning of this year, it has been our intention to restructure RespireRx by creating a fully operational, cannabinoid drug research and development entity in Australia that will have adequate capital to conduct its strategic and operational plans," said Jeff Margolis, Co-Chief Executive Officer and Senior Financial Officer, ResolutionRx and Chief Financial Officer of RespireRx.
In turn, ResolutionRx would be established as an operating company. The companies entered into a License Agreement by way of which the company licensed out its intellectual property, inclusive of patent rights, to ResolutionRx. The license agreement signed between the two parties is worldwide, free of royalties, and exclusive in nature.
The companies had also inked a sublicense agreement by way of which RespireRx sublicensed the rights to the Board of Trustees of the University of Illinois to ResolutionRx. In lieu of the license and sublicensing agreements between the two companies, ResolutionRx issued 25 million ordinary shares of its stock to RespireRx. It was in line with the stock transfer agreement signed by the two companies and also included a payment of $1 million to RespireRx.
Additionally, the companies also entered into a Master Intercompany Services Agreement, pursuant to which RespireRx agreed to provide some support with regard to research, development, and administrative functions.
TPT Global Tech Inc. (OTC:TPTW)
TPT Global Tech Inc. (OTC:TPTW) is a diversified company that operates in a range of sectors like media, telecom, and Smart City Real Estate Development. It has also been successful in the launch of VuMe, the first Super App that functions as a live technology platform.
On August 1, TPT Global signed an Acquisition Agreement for 100% of Broadband Infrastructure Inc.'s outstanding shares. Broadband Infrastructure is involved in the building of fiber optic infrastructure for telecommunications companies and government agencies across the United States. The total price of the acquisition was $9 million, out of which TPT Global paid $6 million in promissory notes and $3 million in its own Series E Preferred Stock.
"Broadband Infrastructure Inc. has a proven track record as a renowned builder of fiber infrastructure throughout the country. Their expertise aligns seamlessly with our vision of delivering cutting-edge technology solutions," said Stephen J. Thomas III, CEO of TPT Global Tech. "This strategic acquisition empowers us to expand our capabilities, providing innovative connectivity solutions to our valued clients, while it may also help us qualify for an uplisting to a major U.S. stock exchange."
The company noted that the Promissory Note could be paid from the funds raised from a Reg A capital raise or through an S-1 registered offering and uplisting on a major stock exchange in the United States. The Series E Preferred Stock could be converted into common stock at a discount of 25% of the market price, and the conversion would be automatic if the company was uplisted on a major exchange.
The transaction is expected to be closed on September 30, 2023, at the latest. In recent times, Broadband Infrastructure has strengthened its reputation as a trusted facilitator for both government agencies and telecom carriers. It holds considerable experience in constructing, designing, and maintaining fiber networks. It is believed that the acquisition could be a major milestone for TPT Global's ambitions for growth and further expansion. The acquisition is also expected to expand the company's presence in the Southeast.
Humanigen Inc. (OTC:HGEN)
Humanigen Inc. (OTC:HGEN) is involved in the development of lenzilumab, a first-in-class antibody that binds to and helps in the neutralization of granulocyte-macrophage colony-stimulating factor. The company is working on the development of lenzilumab for treating acute graft versus host disease (aGvHD) and chronic myelomonocytic leukemia.
On August 7, Humanigen announced that it had been successful in administering the dose of lenzilumab to its first participant as part of the RATing trial. The trial is for administering lenzilumab for the early treatment of those suffering from aGvHD. The trial is being managed by IMPACT, which is a globally renowned accelerated clinical trial network that delivers innovative research in the United Kingdom for stem cell transplant patients.
"We are excited to support of the use of lenzilumab in a clinical trial that addresses the unmet need of aGvHD and helps improve patient outcomes," said Dr. Cameron Durrant, chairman and chief executive officer, Humanigen.
The Director of Stem Cell Transportation of The Christie NHS (National Health Service of the UK) Foundation Trust, Professor Adrian Bloor, spoke about the development as well. He expressed his delight at having treated the first patient and thanked both IMPACT as well as Humanigen and the US Magic Consortium for their support. He went on to add that more patients are going to be enrolled as part of the trial across 18 IMPACT locations in the United Kingdom.
The mortality rate from aGvHD is as high as 70% to 75% and is considered a serious condition. In the RATing trial, lenzilumab would be administered to those patients who had been identified as high-risk as per the MAGIC criteria.
In addition to IMPACT, the other collaborators in the trial are the Cancer Research UK Clinical Trials Unit of the University of Birmingham and the British Society of Blood and Marrow Transplantation.
Disclaimers:CapitalGainsReport (CGR) is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. CapitalGainsReport (CGR) is owned by RazorPitch Inc. and has been retained by Epazz Inc. to assist in the production and distribution of content. 'CGR' is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by CapitalGainsReport/RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. CGR/RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Please visit CapitalGainsReport.com/Disclaimer for full disclaimer.
CONTACT: Mark McKelvie
CapitalGainsReport.com
Editor
585 301 7700
MarkrMcKelvie@gmail.com
.
EPAZZ, INC. 
